Osmotica Pharmaceutical Corp:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Osmotica Pharmaceutical Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7542)・商品コード:DATA904C7542
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:24
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Osmotica Pharmaceutical Corp (Osmotica) is a pharmaceutical company that specializes in drug delivery technologies and neurology based therapies. The company provides product portfolio such as nifedipine, oxybutynin, venlafaxine and desvenlafaxine, among others. It offers capabilities such as formulation research and development, analytical development, bioanalytical development, clinical development and laser drilling technologies, among others. Osmotica primarily provides development of therapies for the treatment of central nervous system (CNS) disorders. The company provides portfolio of products which are in various stages of development focused on the treatment of movement disorders. It also has operational presence in Argentina and Hungary. Osmotica is headquartered in Marietta, Georgia, the US.

Osmotica Pharmaceutical Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Osmotica Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 9
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Vertical Pharma Acquires Portfolio Of Womens Health Products From Upsher-Smith Labs 11
Partnerships 13
Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 13
Vertcal Pharma Enters Into Co-Promotion Agreement With Poly Pharma For Zonatuss 14
Nautilus Neurosciences Enters Into Co-Promotion Agreement With Vertical Pharma For Lorzone 15
Osmotica Pharma Enters Into R&D Agreement With Panacea Biotec For Brand And Generic Products 16
Licensing Agreements 17
Osmotica Pharma Enters into Licensing Agreement with RevitaLid 17
Equity Offering 18
Osmotica Pharma to Raise up to USD132.8 Million in IPO of Shares 18
Acquisition 19
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 19
Osmotica Pharmaceutical Corp – Key Competitors 20
Osmotica Pharmaceutical Corp – Key Employees 21
Osmotica Pharmaceutical Corp – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Key Facts 2
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osmotica Pharmaceutical Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Osmotica Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 9
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vertical Pharma Acquires Portfolio Of Womens Health Products From Upsher-Smith Labs 11
Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 13
Vertcal Pharma Enters Into Co-Promotion Agreement With Poly Pharma For Zonatuss 14
Nautilus Neurosciences Enters Into Co-Promotion Agreement With Vertical Pharma For Lorzone 15
Osmotica Pharma Enters Into R&D Agreement With Panacea Biotec For Brand And Generic Products 16
Osmotica Pharma Enters into Licensing Agreement with RevitaLid 17
Osmotica Pharma to Raise up to USD132.8 Million in IPO of Shares 18
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 19
Osmotica Pharmaceutical Corp, Key Competitors 20
Osmotica Pharmaceutical Corp, Key Employees 21
Osmotica Pharmaceutical Corp, Other Locations 22
Osmotica Pharmaceutical Corp, Subsidiaries 22
Osmotica Pharmaceutical Corp, Joint Venture 23

List of Figures
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Osmotica Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Osmotica Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Osmotica Pharmaceutical Corp:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7542)販売に関する免責事項を必ずご確認ください。
★調査レポート[Osmotica Pharmaceutical Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆